<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>FDA Approval on FinanClub</title>
    <link>https://finan.club/tags/fda-approval/</link>
    <description>Recent content in FDA Approval on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 28 Mar 2024 09:04:22 +0000</lastBuildDate><atom:link href="https://finan.club/tags/fda-approval/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Thu, 28 Mar 2024 09:04:22 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-34
Chances: AstraZeneca&amp;rsquo;s obesity drug shows promising results in early-stage study FDA approves AstraZeneca&amp;rsquo;s Ultomiris for AQP4 Ab+ NMOSD, expanding its product portfolio Beijing&amp;rsquo;s efforts to improve business environment and attract foreign firms could benefit AstraZeneca Ionis&amp;rsquo; collaboration revenues enable it to invest in its pipeline, indicating potential growth Risks: Stock price movement has been relatively volatile in the recent trading sessions Potential impact on AstraZeneca&amp;rsquo;s business from China&amp;rsquo;s changing regulatory environment and foreign investment trends Competition in the pharmaceutical industry may pose risks to AstraZeneca&amp;rsquo;s future growth Continued uncertainty in global economic and political conditions could affect AstraZeneca&amp;rsquo;s operations Score:-34 chances characters count - risks characters count = -34</description>
    </item>
    
    <item>
      <title>IOVA</title>
      <link>https://finan.club/us/iova/</link>
      <pubDate>Wed, 13 Mar 2024 09:07:26 +0000</pubDate>
      
      <guid>https://finan.club/us/iova/</guid>
      <description>score:-12
Chances: Iovance Biotherapeutics&amp;rsquo; revenue is set to grow, indicating potential for increased stock value. The FDA has lifted a partial clinical hold on Iovance&amp;rsquo;s mid-stage study, showing positive regulatory progress. Risks: Iovance Biotherapeutics reported a net loss of $116.4 million in Q4, reflecting financial risk and potential impact on stock performance.</description>
    </item>
    
    <item>
      <title>GKOS</title>
      <link>https://finan.club/us/gkos/</link>
      <pubDate>Wed, 24 Jan 2024 09:05:58 +0000</pubDate>
      
      <guid>https://finan.club/us/gkos/</guid>
      <description>score:12
Chances: Glaukos Corporation continues to benefit from a robust product portfolio and favorable clinical trial results. The FDA approval of Glaukos&amp;rsquo; iDose TR is likely to reshape glaucoma care, promising proactive and durable treatment. Risks: The insider transaction and sale of shares by the President &amp;amp; COO could raise concerns among investors.</description>
    </item>
    
  </channel>
</rss>
